Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Orally Administered ML-007C-MA in Inpatient Adult Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jul 2025 Status changed from not yet recruiting to recruiting.
07 Jul 2025 According to MapLight Therapeutics media release, company announced the initiation of a Phase 2 study to evaluate the efficacy, safety and tolerability of ML-007C-MA. The Phase 2 ZEPHYR study has been designed based on the results of an extensive Phase 1 development program that included 270 healthy volunteers.
05 Jul 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com